Jefferies Boosts Price Target, Estimates on Pfizer (PFE)

Jefferies Boosts Price Target, Estimates on Pfizer (PFE)


Due to an expected big year for clinical drug results, Jefferies analysts increased the price target and earning estimates on pharmaceutical company Pfizer Inc. (PFE).

The analysts maintain a “Buy” rating for PFE and now see shares reaching $31, suggesting a +16.4% upside to Tuesday’s closing price of $26.62.

Pfizer shares were down slightly during premarket trading on Wednesday. The stock is up +21.89% over the past year.

The Bottom Line
We have been recommending shares of Pfizer (PFE) since Mar.2, 2012, when the stock was trading at $21.49. The company has a 3.61% dividend yield, based on last night’s closing stock price of $26.62.

Pfizer Inc. (PFE) is recommended at this time, holding a DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today